deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01639339

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis (BLISS-LN)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab Plus Standard of Care Versus Placebo Plus Standard of Care in Adult Subjects With Active Lupus Nephritis

Sponsor: GlaxoSmithKline

Conditions Lupus Nephritis
Interventions Belimumab 10 mg/kg plus standard therapy Placebo plus standard therapy Standard therapy
Updated 23 times since 2017 Last updated: Feb 23, 2021 Started: Jul 12, 2012 Primary completion: Jul 25, 2019 Completion: Mar 12, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Lupus Nephritis, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 23 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Nov 2017 · 3 months · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~May 2019 · 6 months · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Apr 2020 · 3 months · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jul 2024 · 39 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

23 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Apr 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 18 earlier versions

  1. Jan 2021 — Apr 2021 [monthly]

    Completed PHASE3

  2. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE3

  3. Apr 2020 — Aug 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Jan 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Oct 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

  8. Jul 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  9. May 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE3

  10. Nov 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE3

  11. Sep 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  12. Jul 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  13. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  14. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  15. Nov 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  16. Aug 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  17. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  18. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
  • Human Genome Sciences Inc., a GSK Company
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Beijing, China , Belo Horizonte, Brazil , Belo Horizonte, Minas Gerais, Brazil , Berlin, Germany , Bethlehem, United States , Bogotá, Colombia , Brooklyn, United States , Brussels, Belgium , Buenos Aires, Argentina and 96 more locations